Bone mass regulation by leptin: A hypothalamic control of bone formation;Régulation de la masse osseuse par la leptine: Un contrôle hypothalamique de la formation osseuse

Pathologie Biologie

Volumn 52, Issue 3, 2004, Pages 148-153

  Elefteriou, F ^a   Karsenty, G ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Bone; Hypothalamus; Leptin; Leptine; Os; Osteoblast; Ost oblaste; Sympathetic nervous system; Syst me nerveux sympathique

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOLAMINE; LEPTIN;

ADIPOCYTE; ADRENERGIC SYSTEM; BONE MASS; BRAIN; BRAIN NERVE CELL; CATECHOLAMINE DEPLETION; CELL ACTIVITY; CYTOLOGY; ENERGY METABOLISM; HOMEOSTASIS; HORMONE ACTION; HUMAN; HYPOTHALAMUS; INHIBITION KINETICS; MENOPAUSE; NERVE TRACT; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OVARIECTOMY; PROTEIN ANALYSIS; PUBERTY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

EID: 1842559669     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2003.05.006     Document Type: Article

References (37)

1. Chambers T.J. Regulation of the differentiation and function of osteoclasts. J Pathol. 192:(1):2000;4-13.
2. Duong L.T., Rodan G.A. Regulation of osteoclast formation and function. Rev Endocr Metab Disord. 2:(1):2001;95-104.
3. Ducy P., Schinke T., karsenty G. The osteoblast: A sophisticated fibroblast under central surveillance. Science. 289:2000;1501-1504.
4. karsenty G. Bone formation and factors affecting this process. Matrix Biol. 19:2000;85-89.
5. Karsenty G., Wagner E.F. Reaching a genetic and molecular understanding of skeletal development. Dev Cell. 2:(4):2002;389-406.
6. Cooper C., Melton L.J.I. Magnitude and impact of osteoporosis and fractures. Kelsey J. Osteoporosis. 1996;419-434 Academic Press, San Diego.
7. Riggs B.L., Melton L.J. 3rd. Involutional osteoporosis. N Engl J Med. 314:1986;1676-1686.
8. Riggs B.L., Khosla S., Melton L.J. 3rd. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res. 13:(5):1998;763-773.
9. Felson D.T., Zhang Y., Hannan M.T., Anderson J.J. Effects of weight and body mass index on bone mineral density in men and women: the Framingham study. J Bone Miner Res. 8:(5):1993;567-573.
10. Tremollieres F.A., Pouilles J.M., Ribot C. Vertebral postmenopausal bone loss is reduced in overweight women: a longitudinal study in 155 earlypostmenopausal women. J Clin Endocrinol Metab. 77:1993;683-686.
11. Hla M.M., Davis J.W., Ross P.D., Wasnich R.D., Yates A.J., Ravn P., et al. A multicenter study of the influence of fat and lean mass on bone mineral content: evidence for differences in their relative influence at major fracture sites. Am J Clin Nutr. 64:(3):1996;354-360. Early Postmenopausal Intervention Cohort (EPIC) Study Group.
12. Reid I.R., Ames R., Evans M.C., Sharpe S., Gamble G., France J.T., et al. Determinants of total body and regional bone mineral density in normal postmenopausal women - a key role for fat mass. J Clin Endocrinol Metab. 75:(1):1992;45-51.
13. Friedman J.M., Halaas J.L. Leptin and the regulation of body weight in mammals. Nature. 395:(6704):1998;763-770.
14. Halaas J.L., Gajiwala K.S., Maffei M., Cohen S.L., Chait B.T., Rabinowitz D., et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 269:(5223):1995;543-546.
15. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature. 372:1994;425-432.
16. Fei H., Okano H.J., Li C., Lee G.H., Zhao C., Darnell R., et al. Anatomic localization of alternatively spliced leptin receptors (Ob-R) in mouse brain and other tissues. Proc Natl Acad Sci USA. 94:(13):1997;7001-7005.
17. Huszar D., Lynch C.A., Fairchild-Huntress V., Dunmore J.H., Fang Q., Berkemeier L.R., et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell. 88:(1):1997;131-141.
18. Tartaglia L.A., Dembski M., Weng X., Deng N., Culpepper J., Devos R., et al. Identification and expression cloning of a leptin receptor, OB-R. Cell. 83:(7):1995;1263-1271.
19. Mantzoros C.S., Flier J.S., Rogol A.D. A longitudinal assessment of hormonal and physical alterations during normal puberty in boys. V. Rising leptin levels may signal the onset of puberty. J Clin Endocrinol Metab. 82:(4):1997;1066-1070.
20. Chehab F.F., Lim M.E., Lu R. Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat Genet. 12:(3):1996;318-320.
21. Ducy P., Amling M., Takeda S., Priemel M., Schilling A.F., Beil T., et al. Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass. Cell. 100:2000;197-207.
22. Takeda S., Elefteriou F., Levasseur R., Liu X., Zhao L., Parker K.L., et al. Leptin Regulates Bone Formation via the Sympathetic Nervous System. Cell. 111:(3):2002;305-317.
23. Ahima R.S., Saper C.B., Flier J.S., Elmquist J.K. Leptin regulation of neuroendocrine systems. Frontiers in Neuroendocrinology. 21:(3):2000;263-307.
24. Butler A.A., Marks D.L., Fan W., Kuhn C.M., Bartolome M., Cone R.D. Melanocortin-4 receptor is required for acute homeostatic responses to increased dietary fat. Nat Neurosci. 4:(6):2001;605-611.
25. Cowley M.A., Smart J.L., Rubinstein M., Cerdan M.G., Diano S., Horvath T.L., et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature. 411:(6836):2001;480-484.
26. Young J.B., Landsberg L. Diminished sympathetic nervous system activity in genetically obese (ob/ob) mouse. American Journal of Physiology. 245:(2):1983;E148-E154.
27. Satoh N., Ogawa Y., Katsuura G., Numata Y., Tsuji T., Hayase M., et al. Sympathetic activation of leptin via the ventromedial hypothalamus: leptin-induced increase in catecholamine secretion. Diabetes. 48:(9):1999;1787-1793.
28. Thomas S.A., Matsumoto A.M., Palmiter R.D. Noradrenaline is essential for mouse fetal development. Nature. 374:(6523):1995;643-646.
29. Thomas S.A., Palmiter R.D. Examining adrenergic roles in development, physiology, and behavior through targeted disruption of the mouse dopamine beta-hydroxylase gene. Adv Pharmacol. 42:1998;57-60.
30. Bliziotes M., McLoughlin S., Gunness M., Fumagalli F., Jones S.R., Caron M.G. Bone histomorphometric and biomechanical abnormalities in mice homozygous for deletion of the dopamine transporter gene. Bone. 26:(1):2000;15-19.
31. Thomas S.A., Palmiter R.D. Impaired maternal behavior in mice lacking norepinephrine and epinephrine. Cell. 91:(5):1997;583-592.
32. Serre C.M., Farlay D., Delmas P.D., Chenu C. Evidence for a dense and intimate innervation of the bone tissue, including glutamate-containing fibers. Bone. 25:(6):1999;623-629.
33. Bjurholm A., Kreicbergs A., Terenius L., Goldstein M., Schultzberg M. Neuropeptide Y-, tyrosine hydroxylase- and vasoactive intestinal polypeptide-immunoreactive nerves in bone and surrounding tissues. J Auton Nerv Syst. 25:(2-3):1988;119-125.
34. Bjurholm A., Kreicbergs A., Brodin E., Schultzberg M. Substance P- and CGRP-immunoreactive nerves in bone. Peptides. 9:(1):1988;165-171.
35. Bjurholm A. Neuroendocrine peptides in bone. Int Orthop. 15:(4):1991;325-329.
36. Sisask G., Bjurholm A., Ahmed M., Kreicbergs A. The development of autonomic innervation in bone and joints of the rat. J Auton Nerv Syst. 59:(1-2):1996;27-33.
37. Schwartzman R.J. New treatments for reflex sympathetic dystrophy. N Engl J Med. 343:(9):2000;654-656.